Skip to main content

Table 1 Three-year OS and DFS rates for ENB

From: Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients

Characteristic Total n (%) 3-year 3-year
DFS P OS P
Gender
 Male 111 (64.2) 58.4%   66.1%  
 Female 67 (37.6) 57.0% 0.640 64.7% 0.366
Lymph node metastasis
 (+) 21 (11.2) 33.4%   55.8%  
 (−) 166 (88.8) 59.4% 0.033 67.8% 0.130
Distant metastasis
 (+) 24 (12.8) 34.4%   35.3%  
 (−) 163 (87.2) 60.9% 0.030 70.3% 0.014
Stage
 A 23 (12.5) 74.5%   91.3%  
 B 48 (26.1) 76.1%   91.2%  
 C 113 (61.4) 45.0% 0.000 49.5% 0.000
Treatment
Surgery
 Yes 148 (79.1) 58.9%   72.0%  
 No 39 (20.9) 47.4% 0.038 45.7% 0.000
Extent of resection
 Gross total 106 (77.4) 72.5%   90.1%  
 Subtotal 31 (22.6) 31.4% 0.000 46.8% 0.000
RT
 Yes 153 (81.8) 65.4%   70.8%  
 No 34 (18.2) 22.7% 0.000 49.1% 0.021
CT
 Yes 37 (19.8) 67.4%   69.1%  
 No 150 (80.2) 54.3% 0.162 66.0% 0.472
S + RT ± CT
 Yes 117 (62.6) 69.0%   77.1%  
 No 70 (37.4) 37.1% 0.000 49.8% 0.000
S + RT
 Yes 88 (47.1) 66.5%   76.0%  
 No 99 (52.9) 47.8% 0.019 57.9% 0.011
S + RT ± CT
 S + RT 88 (75.2) 66.5%   76.0%  
 S + RT + CT 29 (24.8) 75.3% 0.283 80.6% 0.589
Recurrence
 Yes 62 (33.2) 14.1%   41.0%  
 No 125 (66.8) 81.6% 0.000 82.8% 0.000
  1. S surgery, CT chemotherapy, RT radiotherapy, Bold indicates significant values
\